^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Viral entry inhibitor

16h
Phase One Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers (clinicaltrials.gov)
P1, N=64, Completed, Godavari Biorefineries Limited | Trial completion date: Apr 2023 --> Nov 2025 | Trial primary completion date: Jan 2023 --> Nov 2025 | Not yet recruiting --> Completed
Trial completion • Trial completion date • Trial primary completion date
6d
A Study to Evaluate Tobevibart+Elebsiran in Chronic Hepatitis Delta Virus (HDV) Infection (ECLIPSE 1) (ACTRN12625000416493)
P3, N=120, Active, not recruiting, Vir Biotechnology, Inc. | Not yet recruiting --> Active, not recruiting
Enrollment closed • Trial initiation date
12d
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P2, N=16, Completed, CytoDyn, Inc. | N=30 --> 16 | Trial completion date: Jul 2022 --> Jan 2025 | Active, not recruiting --> Completed
Trial completion • Enrollment change • Trial completion date • Pan tumor
|
Vyrologix (leronlimab)
12d
Autophagy Plays a Suppressive Role in Bladder Tumor Formation in an Orthotopic Mouse Model and Bladder Cancer Patient Specimens. (PubMed, Kaohsiung J Med Sci)
Notably, amiodarone showed equivalent anti-tumor efficacy but with fewer side effects on the treated mice compared to the clinical anti-cancer drug Mitomycin C (MMC). Similarly, low autophagy is associated with a poor overall survival rate. Furthermore, repurposing amiodarone-induced autophagy accompanied by trivial side effects shows potential for the treatment of bladder cancer patients.
Preclinical • Journal
|
ATG5 (Autophagy Related 5)
|
mitomycin
14d
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1 (clinicaltrials.gov)
P1, N=48, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Recruiting
Enrollment open
19d
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection (clinicaltrials.gov)
P2, N=100, Active, not recruiting, Vir Biotechnology, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2031 --> Jul 2030
Enrollment closed • Trial completion date
1m
Comparative Investigation of the Effects of Adenosine Triphosphate, Melatonin, and Thiamine Pyrophosphate on Amiodarone-Induced Neuropathy and Neuropathic Pain in Male Rats. (PubMed, Biomedicines)
TPP exhibited superior neuroprotective efficacy compared with ATP and melatonin, highlighting its potential as a candidate therapeutic agent for amiodarone-related neuropathy. Further clinical research is warranted to support translational application of these findings.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CAT (Catalase)
1m
Enrollment open • Trial initiation date
2ms
VISTA: HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study (clinicaltrials.gov)
P2, N=75, Recruiting, TaiMed Biologics Inc. | Not yet recruiting --> Recruiting
Enrollment open
2ms
A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery (clinicaltrials.gov)
P=N/A, N=242, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2025
Trial completion • Trial completion date
2ms
PATRONUS: Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery (clinicaltrials.gov)
P4, N=242, Not yet recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Jan 2027
Trial completion date • Trial primary completion date
2ms
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (clinicaltrials.gov)
P1/2, N=33, Completed, Vir Biotechnology, Inc. | Active, not recruiting --> Completed | N=150 --> 33 | Trial completion date: Mar 2027 --> Aug 2025
Trial completion • Enrollment change • Trial completion date